DOCSLIB.ORG

Feline Bronchial Asthma: Treatment*

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Feline Bronchial Asthma: Treatment* Article #2 CE An In-Depth Look: FELINE BRONCHIAL ASTHMA Feline Bronchial Asthma: Treatment* Christopher G. Byers, DVM VCA Veterinary Referral Associates, Inc. Gaithersburg,MD Nishi Dhupa, BVM, MRCVS, DACVECC, DACVIM Cornell University ABSTRACT: Treatment of feline bronchial asthma is directed toward promoting bron- chodilation, reducing inflammation, and restoring normal mucus clearance. Therefore, determining and subsequently eliminating the inciting cause(s) of feline bronchial asthma should be the therapeutic priority of veterinary practitioners. Emergency treatment, including supplemental oxygen ther- apy, glucocorticoids, β2-adrenergic agonists, and methylxanthines, is often indicated. Long-term therapy is aimed at further reducing inflam- matory cell infiltration into the tracheobronchial tree and may be accom- plished with inhalant glucocorticoids and antileukotriene medications. eline bronchial asthma is a reversible respiratory condition of the lower airways char- acterized by altered airway immunosensitivity. Many medications, including β2- Fadrenergic agonists and glucocorticoids, are available for treating acute and chronic feline bronchial asthma (see boxes on page 427; Table 1). In addition, novel therapies, most notably adjuvant magnesium and leukotriene modifiers, are currently being *A companion article on intensely investigated as therapeutic adjuncts in managing feline bronchial asthma. pathophysiology and diagnosis appears on page 418. β2-ADRENERGIC AGONISTS β2-adrenergic agonists are used extensively in treating acute asthmatic patients in Send comments/questions via email veterinary and human medicine; these drugs are the rapid stimulators of β2-adrenergic [email protected] receptors, producing almost immediate relaxation of airway smooth muscle.1–3 or fax 800-556-3288. Albuterol sulfate and terbutaline sulfate are oral β2-adrenergic agonists used in veteri- Visit CompendiumVet.com for nary medicine for their speedy and beneficial effects, including bronchodilation, inhibi- full-text articles, CE testing, and CE tion of acetylcholine release, stabilization of mast cell membranes, reduction of vascular test answers. permeability, and promotion of mucociliary clearance.3 Terbutaline sulfate is also avail- COMPENDIUM 426 June 2005 Treatment CE 427 Drugs Contraindicated for Treatment Protocols for Cats with Acute 2,6 Use with β2-Adrenergic Agonists in Bronchial Asthma Treating Feline Bronchial Asthma Intermittent clinical signs Sympathomimetic amines • Albuterol sulfate inhaler (108 µg as needed) • Isoproterenol (Isuprel, Sanofi Winthrop) • Epinephrine (AmVet Epinephrine 1:1,000, Neogen) Mild to moderate clinical signs • Dopamine (Intropin, Faulding) • Supplemental oxygen therapy • Dobutamine (Dobutrex, Lilly) • Albuterol sulfate inhaler (108 µg as needed) or terbutaline sulfate (0.325–0.625 mg [total dose/cat] Tricyclic antidepressants PO bid or tid) • Imipramine hydrochloride (Tofranil, Novartis) • Theophylline extended release (25 mg/kg PO in the • Imipramine pamoate (Tofranil-PM, Novartis) evening) or aminophylline (6.6 mg/kg PO bid) • Amitriptyline (Elavil, Zeneca) • Prednisolone (1 mg/kg PO bid for 5 days, then 1 • Clomipramine (Clomicalm, Novartis) mg/kg PO sid for 5 days, then 1 mg/kg PO every • Doxepin (Sinequan, Roerig) other day for 5 days) • Fluticasone propionate inhaler (110–220 µg bid) Monoamine oxidase inhibitors • Selegiline hydrochloride (Anipryl, Pfizer) Initial treatment for severe clinical signs • Supplemental oxygen therapy • Albuterol sulfate inhaler (108 µg q30–60min until respiratory distress resolves) or terbutaline sulfate able as an injectable medication and may be adminis- (0.01 mg/kg SC or IM up to q4h) tered subcutaneously or intramuscularly. Administration • Dexamethasone sodium phosphate (1 mg/kg IV of these medications is contraindicated if a patient is or IM) receiving concurrent sympathomimetic amines, tricyclic • Consider adjuvant magnesium administration antidepressants, or monoamine oxidase inhibitors be- After stabilization cause these medications may perpetuate various cardiac • Prednisolone (1 mg/kg PO bid for 5 days, then 1 dysrhythmias (see box on this page). Furthermore, mg/kg PO sid for 5 days, then 1 mg/kg PO every administration of β2-adrenergic agonists should be other day for 5 days) avoided in patients being treated for cardiac disease • Fluticasone propionate inhaler (220 µg bid; wean to lowest possible dose) because these medications have a minimal effect on β1 4 • Albuterol sulfate inhaler (108 µg as needed) receptors in the heart. Stimulation of cardiac β1 recep- tors may evoke tachyarrhythmias; thus all patients receiv- ing β2-adrenergic agonists should be closely monitored for evidence of tachycardia, tremors, central nervous sys- ing the rate of cAMP degradation.3 Methylxanthines tem (CNS) excitement, hypertension, vomiting, mydria- should be cautiously administered to patients with car- sis, and dizziness.4 diac disease because these medications have inotropic and chronotropic effects.4 Tachyarrhythmia may also METHYLXANTHINES develop following methylxanthine administration. These Human and veterinary pharmacology studies have medications also increase gastric acid secretion, and signs demonstrated that methylxanthines inhibit phosphodi- of nausea and vomiting may manifest. Other potential esterase—the enzyme responsible for cAMP degra- signs of methylxanthine intoxication are the results dation.5,6 This class of bronchodilators is the most widely of profound CNS excitation, including nervousness, used and studied in cats with acute asthma, and although excitability, tremors, ataxia, and/or seizures. Both non- the effects of the drugs are rapid, the mechanism of sustained and sustained release products are available for action in feline bronchial asthma remains unclear be- prescription. The bioavailability of orally administered cause methylxanthines do not inhibit phosphodiesterase nonsustained release products is reportedly 100%, at therapeutic levels.3,7,8 Aminophylline and theophylline whereas that of sustained-release products is significantly promote swift bronchodilation, stabilize mast cells, lower.4–7 However, the duration of effect of the sus- increase frequency of ciliary beating, and enhance tained-release medications is longer, allowing lower diaphragmatic contractile strength, possibly by depress- doses and/or reduced dosing frequencies. June 2005 COMPENDIUM 428 CE An In-Depth Look: Feline Bronchial Asthma Table 1. Drugs Commonly Used in Treating Feline Bronchial Asthma4 Drug Brand, Manufacturer Dose Terbutaline sulfate Brethine, Geigy 0.312–0.625 mg (total dose/cat) PO q24h Albuterol sulfate Proventil, Schering 108 µg inhaled as needed Prednisolone Prelone, Muro 1–2 mg/kg/day PO Theophylline extended release Slo-bid, Rhône-Poulenc Rorer 25 mg/kg PO q24h in the evening Theophylline Theolair, 3M Pharmaceuticals 6–8 mg/kg PO bid Fluticasone propionate Flovent, GlaxoSmithKline 44–220 µg inhaled bid Zafirlukast Accolate, AstraZeneca 1–2 mg/kg PO q24h bid Montelukast sodium Singulair, Merck 0.25–0.50 mg/kg/day PO Dexamethasone sodium phosphate Dexaject SP, Vetus 1 mg/kg IV Cyproheptadine hydrochloride Periactin, Merck 1–2 mg PO bid GLUCOCORTICOIDS treating cats with bronchial asthma are prednisolone Glucocorticoids are essential in treating bronchial and prednisone. Prednisone is reduced in the liver via asthma patients in critical condition. These drugs bind glutathione metabolism to form the active hydroxyl to cytosolic receptors, and the glucocorticoid-receptor form—prednisolone; a relatively recent study docu- complexes move to an intranuclear position to alter gene mented reduced glutathione levels in both dogs and cats transcription. Specifically, glucocorticoids are thought to with naturally occurring liver disease.10,11 Thus cats sus- inhibit transcription of proinflammatory mediators, pected of having any level of glutathione depletion most notably interleukin (IL)-5, released in cats with and/or significant underlying hepatic disease may bene- bronchial asthma. These drugs also markedly reduce the fit more from prednisolone therapy. The effects of number of macrophages, lymphocytes, neutrophils, chronic, oral steroid treatment in cats may include eosinophils, and mast cells involved in airway inflamma- insulin resistance, polyuria, cystitis, and inappropriate Acute therapeutic intervention for feline bronchial asthma may involve administration of β2-adrenergic agonists, glucocorticoids, methylxanthines, and magnesium therapy. tion because they decrease the rate of inflammatory cell urination. Therefore, inhaled steroids that do not cause diapedesis and migration, promote apoptosis of these profound systemic effects are gaining popularity. cells, and decrease mucus production. The results of one Glucocorticoids and bronchodilators may be given human study documented that glucocorticoids indirectly effectively by inhalation to cats experiencing acute augment bronchodilation by increasing the number of episodes of bronchial asthma; each class of drug is avail- 12 β2-adrenergic receptors and acting synergistically with able as a metered-dose inhaler (see boxes on page 429). 9 methylxanthines. Glucocorticoids do not have an onset Albuterol sulfate is a β2-adrenergic agonist used as a of action as rapid as β2-adrenergic agonists and/or metered-dose aerosol medication. Fluticasone propionate methylxanthines; thus the benefits of altered gene tran- and beclomethasone dipropionate are more common scription and reduced cellular
Load more

Recommended publications
  • A Vaccination Appointment
    What To Expect: A Vaccination Appointment This page is designed to give you a head's up on what you can expect when you take your pet in for his or her vaccination appointment. The page also discusses what you should expect from your veterinarian during a vaccination appointment. If you have any questions, please call your Shuswap veterinary care team at 250-832-6069. Here’s a basic rationale People and animals use antibodies to fight many viral and bacterial diseases. Your puppy or kitten will have received its first dose of disease fighting antibodies in the first 24 hours of its life, through the consumption of colostrum (first milk) from its mom, provided she was properly immunized. But these antibodies will diminish within a few short weeks. After that period of time it is up to the immune system to make those antibodies in sufficient numbers and thus create immunity. Vaccinations are given to stimulate the immune system to do exactly that. Some diseases require more immune stimulation than others to cause immunity and this is the reason why, for example, the first Rabies vaccine is good for a whole year, whereas the first Parvo or Distemper virus vaccination is only good for about 4 weeks. Currently, the general recommendation is to administer a series of three puppy at 8, 12 and 16 weeks of age with periodic booster vaccinations thereafter and for kitten vaccinations, two vaccinations at 8 and 12 weeks. Your veterinarian will help you work out an appropriate schedule specifically for your pet, as well as what diseases to vaccinate against.
    [Show full text]
  • Fasted and Fed State Human Duodenal Fluids: Characterization, Drug Solubility, and Comparison to Simulated Fluids and with Human Bioavailability
    European Journal of Pharmaceutics and Biopharmaceutics 163 (2021) 240–251 Contents lists available at ScienceDirect European Journal of Pharmaceutics and Biopharmaceutics journal homepage: www.elsevier.com/locate/ejpb Fasted and fed state human duodenal fluids: Characterization, drug solubility, and comparison to simulated fluids and with human bioavailability D. Dahlgren a, M. Venczel b,c, J.-P. Ridoux b,c, C. Skjold¨ a, A. Müllertz d, R. Holm e, P. Augustijns f, P.M. Hellstrom¨ g, H. Lennernas¨ a,* a Department of Pharmaceutical Biosciences, Biopharmaceutics, Uppsala University, Sweden b Global CMC Development Sanofi, Frankfurt, Germany c Global CMC Development Sanofi, Vitry, France d Physiological Pharmaceutics, University of Copenhagen, Copenhagen, Denmark e Drug Product Development, Janssen R&D, Johnson & Johnson, Beerse, Belgium f Drug Delivery and Disposition, KU Leuven, Leuven, Belgium g Department of Medical Sciences, Gastroenterology/Hepatology, Uppsala University, Sweden ARTICLE INFO ABSTRACT Keywords: Accurate in vivo predictions of intestinal absorption of low solubility drugs require knowing their solubility in Bioavailability physiologically relevant dissolution media. Aspirated human intestinal fluids (HIF) are the gold standard, fol­ Food effects lowed by simulated intestinal HIF in the fasted and fed state (FaSSIF/FeSSIF). However, current HIF charac­ Drug solubility terization data vary, and there is also some controversy regarding the accuracy of FaSSIF and FeSSIF for Human intestinal fluids predicting drug solubility in HIF. This study aimed at characterizing fasted and fed state duodenal HIF from 16 Drug absorption Drug dissolution human volunteers with respect to pH, buffer capacity, osmolarity, surface tension, as well as protein, phos­ Drug delivery pholipid, and bile salt content.
    [Show full text]
  • Pharmacokinetic Interactions of Pioglitazone
    Department of Clinical Pharmacology University of Helsinki Finland PHARMACOKINETIC INTERACTIONS OF PIOGLITAZONE Tiina Jaakkola ACADEMIC DISSERTATION To be presented, with the permission of the Medical Faculty of the University of Helsinki, for public examination in Auditorium 2 of Biomedicum, on August 24th, 2007, at 12 noon. Helsinki 2007 JJaakkola_Tiina_vaitos.inddaakkola_Tiina_vaitos.indd 1 117.7.20077.7.2007 221:11:231:11:23 Supervisors: Professor Pertti Neuvonen, MD Department of Clinical Pharmacology University of Helsinki Helsinki, Finland Docent Janne Backman, MD Department of Clinical Pharmacology University of Helsinki Helsinki, Finland Reviewers: Docent Kimmo Malminiemi, MD, MSc Department of Pharmacology, Clinical Pharmacology and Toxicology University of Tampere Tampere, Finland Professor emeritus Pertti Pentikäinen, MD Department of Medicine University of Helsinki Helsinki, Finland Opponent: Professor Kari Kivistö, MD Department of Pharmacology, Clinical Pharmacology and Toxicology University of Tampere Tampere, Finland ISBN 978-952-92-2224-7 (paperback) ISBN 978-952-10-4020-7 (PDF, http://ethesis.helsinki.fi ) Helsinki 2007 Yliopistopaino JJaakkola_Tiina_vaitos.inddaakkola_Tiina_vaitos.indd 2 117.7.20077.7.2007 221:11:551:11:55 JJaakkola_Tiina_vaitos.inddaakkola_Tiina_vaitos.indd 3 117.7.20077.7.2007 221:11:551:11:55 CONTENTS CONTENTS ABBREVIATIONS.......................................................................................................................................... 6 LIST OF ORIGINAL PUBLICATIONS.......................................................................................................
    [Show full text]
  • Pharmacokinetic Interactions of Drugs with St John's Wort
    http://www.paper.edu.cn Pharmacokinetic interactions of Journal of Psychopharmacology 18(2) (2004) 262–276 © 2004 British Association drugs with St John’s wort for Psychopharmacology ISSN 0269-8811 SAGE Publications Ltd, London, Thousand Oaks, CA and New Delhi 10.1177/0269881104042632 Shufeng Zhou Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore. Eli Chan Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore. Shen-Quan Pan Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore. Min Huang Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510089, PR China. Edmund Jon Deoon Lee Department of Pharmacology, Faculty of Medicine, National University of Singapore, Singapore. Abstract There is a worldwide increasing use of herbs which are often cancer patients receiving irinotecan treatment. St John’s wort did not administered in combination with therapeutic drugs, raising the alter the pharmacokinetics of tolbutamide, but increased the incidence potential for herb–drug interactions. St John’s wort (Hypericum of hypoglycaemia. Several cases have been reported that St John’s wort perforatum) is one of the most commonly used herbal antidepressants. A decreased cyclosporine blood concentration leading to organ rejection. literature search was performed using Medline (via Pubmed), Biological St John’s wort caused breakthrough bleeding and unplanned pregnancies Abstracts, Cochrane Library, AMED, PsycINFO and Embase (all from their when used concomitantly with oral contraceptives. It also caused inception to September 2003) to identify known drug interaction with serotonin syndrome when coadministered with selective serotonin- St John’s wort. The available data indicate that St John’s wort is a reuptake inhibitors (e.g.
    [Show full text]
  • Feline Asthma
    Avacta Animal Health Update: Feline Asthma Feline asthma is a common inflammatory disease of the lower airway affecting approximately 1-5% of the cat population and is believed to be triggered by aeroallergens1,2. The median age of presentation is at 4-5 years of age although, it is thought many cats presenting at this time will already have a long-term history of the disease, so the actual age of onset could well be significantly younger2. Clinical signs are variable and are sometimes categorised as acute, where episodic severe respiratory distress on expiration is seen, or as chronic, where more persistent wheezing and coughing of various degrees of severity may be observed1. However, approximately 10-15% of cases will present with a history of vomiting or paroxysmal hacking and coughing. This may result in a diagnostic work-up for gastrointestinal conditions such as hairballs, rather than one for respiratory issues2. Some cats with a history suggestive of asthma may be asymptomatic at the time of presentation. In these patients gentle tracheal palpation will often easily elicit a cough2. The subtly of clinical signs in some cats with chronic disease means the condition can remain undiagnosed for a significant period of time. This delay allows progression of pathological changes within the lung tissue2. Even with a thorough diagnostic respiratory investigation, discriminating feline asthma from other lower airway disorders (including chronic bronchitis and parasitic, infectious, cardiac or neoplastic conditions) is difficult which is, at least in part, why there are relatively few clinical trials into therapeutics for the disease1-3. Diagnosis is usually through a combination of history, clinical signs, thoracic radiography, exclusion of respiratory parasites, bronchoalveolar lavage cytology and response to trial therapy with bronchodilators and glucocorticoids1.
    [Show full text]
  • ACCOLATE® (Zafirlukast) TABLETS DESCRIPTION
    ACCOLATE® (zafirlukast) TABLETS DESCRIPTION Zafirlukast is a synthetic, selective peptide leukotriene receptor antagonist (LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o­ tolylsulfonylbenzamide. The molecular weight of zafirlukast is 575.7 and the structural formula is: The empirical formula is: C31H33N3O6S Zafirlukast, a fine white to pale yellow amorphous powder, is practically insoluble in water. It is slightly soluble in methanol and freely soluble in tetrahydrofuran, dimethylsulfoxide, and acetone. ACCOLATE is supplied as 10 and 20 mg tablets for oral administration. Inactive Ingredients: Film-coated tablets containing croscarmellose sodium, lactose, magnesium stearate, microcrystalline cellulose, povidone, hypromellose, and titanium dioxide. CLINICAL PHARMACOLOGY Mechanism of Action: Zafirlukast is a selective and competitive receptor antagonist of leukotriene D4 and E4 (LTD4 and LTE4), components of slow-reacting substance of anaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma. Patients with asthma were found in one study to be 25­ 100 times more sensitive to the bronchoconstricting activity of inhaled LTD4 than nonasthmatic subjects. In vitro studies demonstrated that zafirlukast antagonized the contractile activity of three leukotrienes (LTC4, LTD4 and LTE4) in conducting airway smooth muscle from laboratory animals and humans. Zafirlukast prevented intradermal LTD4-induced increases in cutaneous vascular permeability and Reference ID: 3407275 inhibited inhaled LTD4-induced influx of eosinophils into animal lungs. Inhalational challenge studies in sensitized sheep showed that zafirlukast suppressed the airway responses to antigen; this included both the early- and late-phase response and the nonspecific hyperresponsiveness.
    [Show full text]
  • Farmacopea De 2021 (Lista De Medicamentos Cubiertos)
    Planes Medicare Advantage de ConnectiCare Plan ConnectiCare Choice 1 (HMO) Plan ConnectiCare Choice 2 (HMO) Plan ConnectiCare Choice 3 (HMO) Plan ConnectiCare Choice Part B Saver Plan ConnectiCare Flex 1 (HMO-POS) Plan ConnectiCare Flex 2 (HMO-POS) Plan ConnectiCare Flex 3 (HMO-POS) Plan ConnectiCare Passage 1 (HMO) Farmacopea de 2021 (Lista de medicamentos cubiertos) LEA LA SIGUIENTE INFORMACIÓN: ESTE DOCUMENTO CONTIENE INFORMACIÓN SOBRE LOS ME- DICAMENTOS QUE CUBRIMOS EN ESTE PLAN. 00021082, V17 Esta farmacopea se actualizó el 09/01/2021. Para obtener información más reciente o si tiene otras preguntas, comuníquese con Servicios para Miembros de ConnectiCare al 1-800-224-2273, los usuarios de TTY deben llamar al 711, de 8.00 am a 8.00 pm, hora del este, los siete días de la semana, o visite connecticare.com/medicare. Última actualización 09/01/2021 H3528_200567_C Nota para los miembros existentes: Esta farmacopea se ha cambiado desde el año pasado. Revise este documento para asegurarse de que aún se incluyan los medicamentos que usted toma. Cuando esta lista de medicamentos (farmacopea) haga referencia a “nosotros”, “nos” o “nuestro”, significa ConnectiCare. Cuando se refiere a “plan” o “nuestro plan”, significa los planes Medicare Advantage de ConnectiCare. Nuestros planes Medicare Advantage incluyen los planes ConnectiCare Choice 1 (HMO), ConnectiCare Choice 2 (HMO), ConnectiCare Choice 3 (HMO), ConnectiCare Choice Part B Saver, ConnectiCare Flex 1 (HMO-POS), ConnectiCare Flex2 (HMO-POS), ConnectiCare Flex 3 (HMO-POS) y ConnectiCare Passage 1 (HMO). Este documento incluye una lista de los medicamentos (farmacopea) para nuestro plan que se encuentra vigente desde el 09/01/2021 .
    [Show full text]
  • Medicare Part D: 2021 Value Plan Formulary
    | Value Plan | Express Scripts Medicare (PDP) 2021 Formulary (List of Covered Drugs) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN Formulary ID Number: 21095, Version 10 This formulary was updated on 9/1/2021. For more recent information or other questions, please contact Express Scripts Medicare® (PDP) Customer Service at 1.800.758.4574; New York State residents: 1.800.758.4570 or, for TTY users, 1.800.716.3231, 24 hours a day, 7 days a week, or visit express-scripts.com. Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take. When this drug list (formulary) refers to “we,” “us,” or “our,” it means Medco Containment Life Insurance Company and Medco Containment Insurance Company of New York (for members located in New York State only). When it refers to “plan” or “our plan,” it means Express Scripts Medicare. This document includes a list of the drugs (formulary) for our plan, which is current as of September 1, 2021. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network and/or copayments/coinsurance may change on January 1, 2022, and from time to time during the year. What is the Express Scripts Medicare Formulary? A formulary is a list of covered drugs selected by Express Scripts Medicare in consultation with a team of healthcare providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program.
    [Show full text]
  • Clinical Pharmacokinetics and Pharmacodynamics CONCEPTS and APPLICATIONS 18048 FM.Qxd 11/11/09 4:31 PM Page Iii
    18048_FM.qxd 11/11/09 4:31 PM Page i Clinical Pharmacokinetics and Pharmacodynamics CONCEPTS AND APPLICATIONS 18048_FM.qxd 11/11/09 4:31 PM Page iii FOURTH EDITION Clinical Pharmacokinetics and Pharmacodynamics Concepts and Applications Malcolm Rowland, DSc, PhD Thomas N. Tozer, PharmD, PhD Professor Emeritus Professor Emeritus School of Pharmacy and School of Pharmacy and Pharmaceutical Sciences Pharmaceutical Sciences University of Manchester University of California, San Francisco Manchester, United Kingdom Adjunct Professor of Pharmacology Skaggs School of Pharmacy and Pharmaceutical Sciences University of California San Diego With Online Simulations by Hartmut Derendorf, PhD Distinguished Professor Guenther Hochhaus, PhD Associate Professor Department of Pharmaceutics University of Florida Gainesville, Florida 18048_FM.qxd 11/11/09 4:31 PM Page iv Acquisitions Editor: David B. Troy Product Manager: Matt Hauber Marketing Manager: Allison Powell Designer: Doug Smock Compositor: Maryland Composition Inc./ASI Fourth Edition Copyright © 2011 Lippincott Williams & Wilkins, a Wolters Kluwer business 351 West Camden Street 530 Walnut Street Baltimore, MD 21201 Philadelphia, PA 19106 Printed in China All rights reserved. This book is protected by copyright. No part of this book may be reproduced or transmitted in any form or by any means, including as photocopies or scanned-in or other electronic copies, or utilized by any information storage and retrieval system without written permission from the copyright owner, except for brief quotations embodied in critical articles and reviews. Materials appearing in this book prepared by individuals as part of their official duties as U.S. government em- ployees are not covered by the above-mentioned copyright. To request permission, please contact Lippincott Williams & Wilkins at 530 Walnut Street, Philadelphia, PA 19106, via email at permis- [email protected], or via website at lww.com (products and services).
    [Show full text]
  • Anesthesia/Anti-Convulsants: Carbamazepine Ethosuximide Halothane Lidocaine Phenytoin Valproic Acid Antibiotics: Aminoglycosides
    DRUGS Anesthesia/Anti-Convulsants: Carbamazepine Ethosuximide Halothane Lidocaine Phenytoin Valproic Acid Antibiotics: Aminoglycosides (Generic Examples: Gentamycin; Tobramycin; Amikacin) Amoxicillin Amphotericin B Ampicillin Azithromycin (A Special Macrolide) Ceftriaxone (Prototype 3rd Generation Cephalosporin) Chloramphenicol Chloroquine, Quinine and Mefloquine Ciprofloxacin (Prototype Fluoroquinolone) Clindamycin Demeclocycline (Another Tetracycline) Doxycycline (Prototype Tetracycline) Erythromycin (Prototype Macrolide) Indinavir Isoniazid Ketoconazole Metronidazole Nafcillin (Beta-Lactamase Resistant Penicillin) Praziquantel Rifampin Trimethoprim + Sulfamethoxazole Vancomycin Zidovudine Autonomic Drugs : Atropine Bethanechol Clonidine Cocaine Dobutamine Edrophonium Epinephrine Isoproteronol Labetalol (also Carvedilol) Methylphenidate Metoprolol Phenoxybenzamine Phentolamine Phenylepherine Physostigmine Pilocarpine Pindolol (also Acebutolol) Prazosin Propranolol Reserpine Ritodrine Blood D/O Drugs: Heparin Streptokinase TPA (Tissue Plasminogen Activator) Warfarin Cancer Drugs: 5-Fluoruracil + Folic Acid Bleomycin Busulfan Cisplatin Colchicine Cyclophoshamide Cyclosporine Dacarbazine Doxorubicin = Adriamycin Melphalan Methotrexate Vinchristine Cardiovascular Drugs: Amiodarone Captopril and Enalapril Digoxin Diltiazem Hydralazine Lidocaine Losartan Nifedipine Nitroglycerin and Isosorbide Dinitrate Nitroprusside Procainamide Quinidine Verapamil CNS Drugs: Alprazolam (Another Benzodiazepine) Desipramine (Secondary TCA) Diazepam (Prototype
    [Show full text]
  • CFA EXECUTIVE BOARD MEETING FEBRUARY 4/5, 2017 Index To
    CFA EXECUTIVE BOARD MEETING FEBRUARY 4/5, 2017 Index to Minutes Secretary’s note: This index is provided only as a courtesy to the readers and is not an official part of the CFA minutes. The numbers shown for each item in the index are keyed to similar numbers shown in the body of the minutes. (1) MEETING CALLED TO ORDER. .................................................................................... 3 (2) ADDITIONS/CORRECTIONS; RATIFICATION OF ON-LINE MOTIONS. ................ 5 (3) APPEAL HEARING. ....................................................................................................... 12 (4) PROTEST COMMITTEE. ............................................................................................... 13 (5) INVESTMENT PRESENTATION. ................................................................................. 14 (6) CENTRAL OFFICE OPERATIONS. .............................................................................. 15 (7) MARKETING................................................................................................................... 18 (8) BOARD CITE. .................................................................................................................. 20 (9) JUDGING PROGRAM. ................................................................................................... 29 (10) REGIONAL ASSIGNMENT ISSUE. .............................................................................. 34 (11) PERSONNEL ISSUES. ...................................................................................................
    [Show full text]
  • APR 2020 Part A.Pdf
    1 HZS C2BRNE DIARY – April 2020 www.cbrne-terrorism-newsletter.com 2 HZS C2BRNE DIARY – April 2020 HZS C2BRNE DIARY– 2020© April 2020 Website: www.cbrne-terrorism-newsletter.com Editor-in-Chief BrigGEN (ret.) Ioannis Galatas MD, MSc, MC (Army) PhD cand Consultant in Allergy & Clinical Immunology Medical/Hospital CBRNE Planner & Instructor Senior Asymmetric Threats Analyst Manager, CBRN Knowledge Center @ International CBRNE Institute (BE) Senior CBRN Consultant @ HotZone Solutions Group (NL) Athens, Greece Contact e-mail: [email protected] Editorial Team ⚫ Bellanca Giada, MD, MSc (Italy) ⚫ Hopmeier Michael, BSc/MSc MechEngin (USA) ⚫ Kiourktsoglou George, BSc, Dipl, MSc, MBA, PhD (UK) ⚫ Photiou Steve, MD, MSc EmDisaster (Italy) ⚫ Tarlow Peter, PhD Sociol (USA) A publication of HotZone Solutions Group Prinsessegracht 6, 2514 AN, The Hague, The Netherlands T: +31 70 262 97 04, F: +31 (0) 87 784 68 26 E-mail: [email protected] DISCLAIMER: The HZS C2BRNE DIARY® (former CBRNE-Terrorism Newsletter), is a free online publication for the fellow civilian/military CBRNE First Responders worldwide. The Diary is a collection of papers/articles related to the stated thematology. Relevant sources/authors are included and all info provided herein is from open Internet sources. Opinions and comments from the Editor, the Editorial Team or the authors publishing in the Diary do not necessarily represent those of the HotZone Solutions Group (NL) or the International CBRNE Institute (BE). www.cbrne-terrorism-newsletter.com 3 HZS C2BRNE DIARY – April
    [Show full text]